{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:14:13Z","timestamp":1791389653978,"version":"4.3.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/bjc.2017.94","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T22:47:26Z","timestamp":1492728446000},"page":"1415-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity"],"prefix":"10.1038","volume":"116","author":[{"given":"Didier","family":"Meulendijks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M","family":"Henricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart A W","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abidin","family":"Aliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"van Werkhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonius","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M P W","family":"Mandigers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Soesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Cats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H M","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"key":"BFbjc201794_CR1","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-14-2817","volume":"21","author":"U Amstutz","year":"2015","unstructured":"Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiad\u00e8r CR (2015) Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 21: 2038\u20132044.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201794_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J R Stat Soc B 57: 289\u2013300.","journal-title":"J R Stat Soc B"},{"key":"BFbjc201794_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249: 271\u2013282.","journal-title":"Cancer Lett"},{"key":"BFbjc201794_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/clpt.2013.172","volume":"94","author":"KE Caudle","year":"2013","unstructured":"Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 94: 640\u2013645.","journal-title":"Clin Pharmacol Ther"},{"key":"BFbjc201794_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2710.2004.00569.x","volume":"29","author":"J Ciccolini","year":"2004","unstructured":"Ciccolini J, Mercier C, Blachon M-F, Favre R, Durand A, Lacarelle B (2004) A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 29: 307\u2013315.","journal-title":"J Clin Pharm Ther"},{"key":"BFbjc201794_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PHM, Rosing H, Mandigers CMPWPW, Soesan M, Beijnen JH, Schellens JHMM (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34: 227\u2013234.","journal-title":"J Clin Oncol"},{"key":"BFbjc201794_CR7","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Ren\u00e9e N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248\u20132253.","journal-title":"J Clin Oncol"},{"issue":"16-17","key":"BFbjc201794_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.clinbiochem.2016.07.004","volume":"49","author":"AFA Galarza","year":"2016","unstructured":"Galarza AFA, Linden R, Antunes MV, Hahn RZ, Raymundo S, da Silva ACC, Staggemeier R, Spilki FR, Schwartsmann G (2016) Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clin Biochem 49 (16-17): 1221\u20131226.","journal-title":"Clin Biochem"},{"key":"BFbjc201794_CR9","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","volume":"17","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M, Gu\u00e9rin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17: 1105.","journal-title":"J Clin Oncol"},{"key":"BFbjc201794_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-2125.2005.02472.x","volume":"60","author":"S Ito","year":"2005","unstructured":"Ito S, Kawamura T, Inada M, Inoue Y, Hirao Y, Koga T, Kunizaki J, Shimizu T, Sato H (2005) Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. Br J Clin Pharmacol 60: 584\u2013593.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"BFbjc201794_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bcp.13007","volume":"82","author":"BAW Jacobs","year":"2016","unstructured":"Jacobs BAW, Deenen MJ, Pluim D, van Hasselt JGC, Kr\u00e4henb\u00fchl MD, van Geel RMJM, de Vries N, Rosing H, Meulendijks D, Burylo A, Cats AM, Beijnen JH, Huitema ADR, Schellens JHM (2016a) Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol 82 (3): 706\u2013716.","journal-title":"Br J Clin Pharmacol"},{"key":"BFbjc201794_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","volume":"126","author":"BAW Jacobs","year":"2016","unstructured":"Jacobs BAW, Rosing H, de Vries N, Meulendijks D, Henricks LM, Schellens JHM, Beijnen JH (2016b) Development and validation of a rapid and sensitive UPLC\u2013MS\/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm Biomed Anal 126: 75\u201382.","journal-title":"J Pharm Biomed Anal"},{"key":"BFbjc201794_CR13","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1177\/0091270004268911","volume":"44","author":"H Jiang","year":"2004","unstructured":"Jiang H, Lu J, Jiang J, Hu P (2004) Important role of the dihydrouracil\/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 44: 1260\u20131272.","journal-title":"J Clin Pharmacol"},{"key":"BFbjc201794_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","volume":"41","author":"MR Johnson","year":"2001","unstructured":"Johnson MR, Diasio RB (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41: 151\u2013157.","journal-title":"Adv Enzyme Regul"},{"key":"BFbjc201794_CR15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1177\/147323001003800413","volume":"38","author":"MH Kristensen","year":"2010","unstructured":"Kristensen MH, Pedersen P, Mejer J (2010) The value of dihydrouracil\/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 38: 1313\u20131323.","journal-title":"J Int Med Res"},{"key":"BFbjc201794_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"ABP van Kuilenburg","year":"2004","unstructured":"van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40: 939\u2013950.","journal-title":"Eur J Cancer"},{"key":"BFbjc201794_CR17","first-page":"4705","volume":"6","author":"ABP van Kuilenburg","year":"2000","unstructured":"van Kuilenburg ABP, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6: 4705\u20134712.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201794_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","volume":"46","author":"ABP Van Kuilenburg","year":"2000","unstructured":"Van Kuilenburg ABP, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH (2000) Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 46: 9\u201317.","journal-title":"Clin Chem"},{"key":"BFbjc201794_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ijc.10599","volume":"101","author":"ABP Van Kuilenburg","year":"2002","unstructured":"Van Kuilenburg ABP, Meinsma R, Zoetekouw L, Van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 101: 253\u2013258.","journal-title":"Int J Cancer"},{"key":"BFbjc201794_CR20","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB (2006) Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 12: 5491\u20135495.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201794_CR21","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/ijc.30014","volume":"138","author":"D Meulendijks","year":"2016","unstructured":"Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiad\u00e8r CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JHM (2016) Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. Int J Cancer 138: 2752\u20132761.","journal-title":"Int J Cancer"},{"key":"BFbjc201794_CR22","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiad\u00e8r CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg ABP, Punt CJA, Koopman M, Beijnen JH, Cats A, Schellens JHM (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16: 1639\u20131650.","journal-title":"Lancet Oncol"},{"key":"BFbjc201794_CR23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14740338.2010.511610","volume":"9","author":"SE Mikhail","year":"2010","unstructured":"Mikhail SE, Sun JF, Marshall JL (2010) Safety of capecitabine: a review. Expert Opin Drug Saf 9: 831\u2013841.","journal-title":"Expert Opin Drug Saf"},{"key":"BFbjc201794_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","volume":"79","author":"G Milano","year":"1999","unstructured":"Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Ren\u00e9e N (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79: 627\u2013630.","journal-title":"Br J Cancer"},{"key":"BFbjc201794_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","volume":"71","author":"F Mueller","year":"2013","unstructured":"Mueller F, B\u00fcchel B, K\u00f6berle D, Sch\u00fcrch S, Pfister B, Kr\u00e4henb\u00fchl S, Froehlich TK, Largiader CR, Joerger M (2013) Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol 71: 361\u2013370.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc201794_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-13-0878","volume":"13","author":"SM Offer","year":"2014","unstructured":"Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB (2014) microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 13: 742\u2013751.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc201794_CR27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","volume":"32","author":"D Rosmarin","year":"2014","unstructured":"Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi M-C, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon J-P, Midgley R, Kerr D, Tomlinson I, Astrup Jensen S (2014) Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. J Clin Oncol 32: 1031\u20131039.","journal-title":"J Clin Oncol"},{"key":"BFbjc201794_CR28","unstructured":"Scrip\u2019s Cancer Chemotherapy Report, Scrip\u2019s World Pharmaceutical News (2002). PJB Publications Ltd: London, UK."},{"key":"BFbjc201794_CR29","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2217\/pgs.14.126","volume":"15","author":"J Sistonen","year":"2014","unstructured":"Sistonen J, B\u00fcchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, van Kuilenburg AB, Largiad\u00e8r CR (2014) Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 15: 1653\u20131666.","journal-title":"Pharmacogenomics"},{"key":"BFbjc201794_CR30","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00280-011-1661-5","volume":"68","author":"MC van Staveren","year":"2011","unstructured":"van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, van Kuilenburg ABP, Maring JG (2011) Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol 68: 1611\u20131617.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc201794_CR31","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1002\/cncr.26595","volume":"118","author":"Y Wettergren","year":"2012","unstructured":"Wettergren Y, Carlsson G, Odin E, Gustavsson B (2012) Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. Cancer 118: 2935\u20132943.","journal-title":"Cancer"},{"key":"BFbjc201794_CR32","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1086\/429864","volume":"76","author":"JE Wigginton","year":"2005","unstructured":"Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76: 887\u2013893.","journal-title":"Am J Hum Genet"},{"key":"BFbjc201794_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bbaexp.2006.05.001","volume":"1759","author":"X Zhang","year":"2006","unstructured":"Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB (2006) The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim Biophys Acta 1759: 247\u2013256.","journal-title":"Biochim Biophys Acta"},{"key":"BFbjc201794_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000099984","volume":"53","author":"ZW Zhou","year":"2007","unstructured":"Zhou ZW, Wang GQ, Wan D, Sen, Lu ZH, Chen YB, Li S, Chen G, Pan ZZ (2007) The dihydrouracil\/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 53: 127\u2013131.","journal-title":"Chemotherapy"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201794.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201794","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.94","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201794.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T18:03:07Z","timestamp":1719165787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFbjc201794"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.94","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]},"assertion":[{"value":"14 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}